Common progenitor cells in mature B-cell malignancies: Implications for therapy

Current Opinion in Hematology

Volumn 21, Issue 4, 2014, Pages 333-340

  Green, Michael R ^a   Alizadeh, Ash A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clonal evolution; Common progenitor cell; Follicular lymphoma; Multiple myeloma

Indexed keywords

FOLLICULAR LYMPHOMA; GENE DOSAGE; GENE FREQUENCY; GENOMIC INSTABILITY; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE MYELOMA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOMATIC HYPERMUTATION; SOMATIC MUTATION; STEM CELL; ANIMAL; CANCER STEM CELL; CLONAL EVOLUTION; DRUG EFFECTS; GENETICS; LYMPHOMA, FOLLICULAR; METABOLISM; MUTATION; PATHOLOGY; PRE B LYMPHOCYTE;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLONAL EVOLUTION; HUMANS; LYMPHOMA, FOLLICULAR; MULTIPLE MYELOMA; MUTATION; NEOPLASTIC STEM CELLS; PRECURSOR CELLS, B-LYMPHOID;

EID: 84902275099     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000049     Document Type: Review

References (57)

1. Garraway L, Lander E. Lessons from the cancer genome. Cell 2013; 153:17-37.
2. Kandoth C, McLellan M, Vandlion F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502:333-339.
3. Vogelstein B, Papadopoulos N, Velculescu V, et al. Cancer genome landscapes. Science 2013; 339:1546-1558.
4. Lawrence M, Stojanov P, Mermel C, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505:495-501.
5. Garraway L, Verweij J, Ballman K. Precision oncology: an overview. J Clin Oncol 2013; 31:1803-1805.
6. Rampal R, Levine R. Leveraging cancer genome information in hematologic malignancies. J Clin Oncol 2013; 31:1885-1892.
7. Green M, Gentles A, Nair R, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013; 121:1604-1611.
8. Durnick S, Ho C, Wang N, et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Disc 2011; 1:137-143.
9. Landau D, Carter S, Getz G, Wu C. Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 2014; 28:34-43.
10. Dick J. Stem cell concepts renew cancer research. Blood 2008; 112:4793-4807.
11. Martinez-Climent J, Fontan L, Gascoyne R, et al. Lymphoma stem cells: enough evidence to support their existence? Haematologica 2010; 95:293-302.
12. Greaves M, Maley C. Clonal evolution in cancer. Nature 2012; 481:306-313.
13. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5:251-262.
14. Kridel R, Sehn L, Gascoyne R. Pathogenesis of follicular lymphoma. J Clin Invest 2012; 122:3424-3431.
15. Carbone A, Santoro A. How I treat: diagnosing and managing in situ lymphoma. Blood 2011; 117:3954-3960.
16. Jegalian A, Eberle F, Pack S, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 2011; 118:2976-2984.
17. Smith S. Dissecting follicular lymphoma: high versus low risk. ASH Education Program Book 2013; 2013:561-567.
18. Bernstein S, Burack W. The incidence, natural history, biology, and treatment of transformed lymphomas. ASH Education Program Book 2009; 532-541.
19. Link B, Maurer M, Nowakowski G, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol 2013; 31:3272-3278.
20. Tsujimoto Y, Cossman J, Jaffe E, Croce C. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228:1440-1443.
21. Tsujimoto Y, Gorham J, Cossman J, et al. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229:1390-1393.
22. Tsai A, Lu H, Raghavan S, et al. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 2008; 135:1130-1142.
23. Nussenzweig A, Nussenzweig M. Origin of chromosomal translocations in lymphoid cancer. Cell 2010; 141:27-38.
24. Roulland S, Navarro J, Grenot P. Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis. J Exp Med 2006; 203:2425-2431.
25. Matolcsy A, Schattner E, Knowles D, Casali P. Clonal evolution of B cells in transformation from low- to high-grade lymphoma. Eur J Immunol 1999; 29:1253-1264.
26. Zhu D, Hawkins R, Hamblin T, Stevenson F. Clonal history of a human follicular lymphoma as revealed in the immunoglobulin variable region genes. Br J Haematol 1994; 86:505-512.
27. Zelenetz A, Chen T, Levy R. Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J Exp Med 1992; 176:1137-1148.
28. Bahler D, and Levy R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc Natl Acad Sci USA 1992; 89:6770-6774.
29. Carlotti E, Wrench D, Matthews J, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood 2009; 113:3553-3557.
30. dAmore F, Chan E, Iqbal J, et al. Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways and frequent parallel clonal evolution. Clin Cancer Res 2008; 14:7180-7187.
31. Eide M, Liestol K, Lingaerde O, et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood 2010; 116:1489-1497.
32. Mamessier E, Song J, Eberle F, et al. Early lesions in follicular lymphoma: a genetic perspective. Haematologica 2014; 99:481-488.
33. Weigert O, Kopp N, Lane A, et al. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Disc 2012; 2:47-55.
34. Bodor C, Grossman V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013; 122:3165-3168.
35. Knutson S, Wigle T, Warholic N, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8:890-896.
36. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 2012; 109:21360-21365.
37. McCabe M, Ott H, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492:108-112.
38. Okosun J, Bodor C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014; 46:176-181.
39. Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep 2014; 6:1-11.
40. Morgan G, Walker B, Davies F. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12:335-348.
41. Chapman M, Lawrence M, Keats J, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467-472.
42. Lohr J, Stolanov P, Carter S, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25:91-101.
43. Walker B, Wardell C, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 2014; 28:384-390.
44. Keats J, Chesi M, Egan J, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120:1067-1076.
45. Egan J, Shi C, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120:1060-1066.
46. Bolli N, Avet-Loiseau H, Wedge D, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014; 5:2997.
47. Magrangeas F, Avet-Loiseau H, Gouraud W, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2013; 27:473-481.
48. Melchor L, Brioli A, Wardell C, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia 2014. [Epub ahead of print]
49. Klein U, Dalla-Favera R. Germinal centers: role in B-cell physiology and malignancy. Nat Rev Immunol 2008; 8:22-33.
50. Walker B, Wardell C, Johnson D, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 2013; 121:3413-3419.
51. Green M, Vicente-Dueñas C, Romero-Camarero I, et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat Comm 2014. (in press).
52. Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011; 20:246-259.
53. Messmer B, Albesiano E, Efremov D, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004; 200:519-525.
54. Duhren-von Minden M, Ubelhart R, Schneider D, et al. Chronic lymphocytic leukemia is driven by antigen-independent cell-autonomous signaling. Nature 2012; 489:309-312.
55. Sachen K, Stohman M, Singletary J, et al. Self-antigen recognition by follicular lymphoma B-cell receptors. Blood 2012; 120:4182-4190.
56. Landau D, Carter S, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152:714-726.
57. Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013; 110:1398-1403.